Imidazopyrimidines, potent inhibitors of p38 MAP kinase

Kenneth C. Rupert, James R. Henry, John H. Dodd, Scott A. Wadsworth, Druie E. Cavender, Gilbert C. Olini, Bohumila Fahmy, John J. Siekierka

Research output: Contribution to journalArticlepeer-review

274 Scopus citations


The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-α and IL-1β. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-α in vivo.

Original languageEnglish
Pages (from-to)347-350
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Issue number3
StatePublished - Feb 2003


Dive into the research topics of 'Imidazopyrimidines, potent inhibitors of p38 MAP kinase'. Together they form a unique fingerprint.

Cite this